A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

NCT04735822 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Part 1: Belumosudil 40 mg/mL Sequence ABFCED
DRUG: Part 1: Belumosudil 40 mg/mL Sequence BCADFE
DRUG: Part 1: Belumosudil 40 mg/mL Sequence CDBEAF
DRUG: Part 1: Belumosudil 40 mg/mL Sequence DECFBA
DRUG: Part 1: Belumosudil 40 mg/mL Sequence EFDACB
DRUG: Part 1: Belumosudil 40 mg/mL Sequence FAEBDC
DRUG: Part 2: Belumosudil 200 mg Sequence GHI
DRUG: Part 2: Belumosudil 200 mg Sequence HIG
DRUG: Part 2: Belumosudil 200 mg Sequence IGH
DRUG: Part 2: Belumosudil 200 mg Sequence IHG
DRUG: Part 2: Belumosudil 200 mg Sequence GIH
DRUG: Part 2: Belumosudil 200 mg Sequence HGI

Sponsor

Kadmon Corporation, LLC

Collaborators

[object Object]